3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
6
Uterine Cervical Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
von Hippel-Lindau Disease
1
Vulvar Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Penile Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Brain Neoplasms
1
Bone Neoplasms
1
Advanced Malignancies
1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
1
Adenocarcinoma
1
Interventions
pembrolizumab
2
tremelimumab
1
poly ICLC
1
lenvatinib
1
durvalumab
1
balstilimab
1
Peptides
1
Pemetrexed
1
Carboplatin
1
Blood Specimen Collection
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
lenvatinib
×
30 days
×
Clear all
NCT04305054
2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
335 enrolled